JP2024532489A5 - - Google Patents
Info
- Publication number
- JP2024532489A5 JP2024532489A5 JP2024513973A JP2024513973A JP2024532489A5 JP 2024532489 A5 JP2024532489 A5 JP 2024532489A5 JP 2024513973 A JP2024513973 A JP 2024513973A JP 2024513973 A JP2024513973 A JP 2024513973A JP 2024532489 A5 JP2024532489 A5 JP 2024532489A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- sequence shown
- binding protein
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021902832 | 2021-09-01 | ||
| AU2021902832A AU2021902832A0 (en) | 2021-09-01 | Methods and compositions for stimulating immune activity | |
| PCT/AU2022/051066 WO2023028653A1 (en) | 2021-09-01 | 2022-09-01 | Novel dysfunctional p2x7 binders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532489A JP2024532489A (ja) | 2024-09-05 |
| JP2024532489A5 true JP2024532489A5 (enExample) | 2025-08-01 |
Family
ID=85410590
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513926A Pending JP2024532482A (ja) | 2021-09-01 | 2022-09-01 | 免疫活性を刺激するための方法および組成物 |
| JP2024513973A Pending JP2024532489A (ja) | 2021-09-01 | 2022-09-01 | 新規の機能不全ｐ２ｘ７結合剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513926A Pending JP2024532482A (ja) | 2021-09-01 | 2022-09-01 | 免疫活性を刺激するための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20240368282A1 (enExample) |
| EP (2) | EP4395813A4 (enExample) |
| JP (2) | JP2024532482A (enExample) |
| CN (2) | CN117881421A (enExample) |
| AU (2) | AU2022335932A1 (enExample) |
| CA (2) | CA3223079A1 (enExample) |
| MX (2) | MX2023015469A (enExample) |
| WO (2) | WO2023028657A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3240805T3 (fi) * | 2014-12-15 | 2025-02-17 | Univ California | Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori |
| US20220267450A1 (en) * | 2020-10-14 | 2022-08-25 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| EP4384219A4 (en) | 2021-08-10 | 2025-06-18 | Viridian Therapeutics, Inc. | COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE |
| AU2024232401A1 (en) * | 2023-03-08 | 2025-08-21 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors for binding to dysfunctional p2x 7 receptor |
| WO2024211413A2 (en) * | 2023-04-05 | 2024-10-10 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Trogocytosis in cancer cells and methods for treating cancer related thereto |
| WO2024220870A1 (en) * | 2023-04-19 | 2024-10-24 | The University Of Chicago | Antibody-targeted enzymatic chemoprotection |
| AU2024269870A1 (en) * | 2023-05-05 | 2025-11-20 | Board Of Regents, The University Of Texas System | Multi-receptor natural killer cells |
| EP4735479A1 (en) * | 2023-06-30 | 2026-05-06 | Biosceptre (Aust) Pty Ltd | Molecules and methods for activating car t cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2467404B1 (en) * | 2009-08-20 | 2015-09-30 | Biosceptre International Limited | Anti p2x7 receptor antibodies and fragments thereof |
| WO2011075789A1 (en) * | 2009-12-24 | 2011-06-30 | Biosceptre International Limited | Antibodies to non-functional oligomeric p2x7 receptors |
| US20180037650A1 (en) * | 2015-04-02 | 2018-02-08 | Biosceptre (Uk) Limited | Pain Treatment |
| US12121539B2 (en) * | 2015-09-11 | 2024-10-22 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors and uses thereof |
| MX2019004410A (es) * | 2016-10-21 | 2019-09-26 | Biosceptre Uk Ltd | Particulas citotoxicas. |
| CN112166193A (zh) * | 2018-05-21 | 2021-01-01 | 生物权威（英国）有限公司 | 具有经修饰的接头结构域的嵌合抗原受体及其用途 |
| US20220177583A1 (en) * | 2019-03-20 | 2022-06-09 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
| CN113853388B (zh) * | 2019-03-27 | 2024-07-19 | 加拿大国家研究委员会 | 抗-egfrviii抗体及其抗原结合片段 |
| EP4304610A4 (en) * | 2021-03-11 | 2025-03-05 | Biosceptre (Aust) Pty Ltd | Novel cell therapy system |
-
2022
- 2022-09-01 US US18/688,086 patent/US20240368282A1/en active Pending
- 2022-09-01 EP EP22862427.6A patent/EP4395813A4/en active Pending
- 2022-09-01 MX MX2023015469A patent/MX2023015469A/es unknown
- 2022-09-01 US US18/686,554 patent/US20240376193A1/en active Pending
- 2022-09-01 CA CA3223079A patent/CA3223079A1/en active Pending
- 2022-09-01 WO PCT/AU2022/051070 patent/WO2023028657A1/en not_active Ceased
- 2022-09-01 WO PCT/AU2022/051066 patent/WO2023028653A1/en not_active Ceased
- 2022-09-01 JP JP2024513926A patent/JP2024532482A/ja active Pending
- 2022-09-01 AU AU2022335932A patent/AU2022335932A1/en active Pending
- 2022-09-01 JP JP2024513973A patent/JP2024532489A/ja active Pending
- 2022-09-01 CA CA3223086A patent/CA3223086A1/en active Pending
- 2022-09-01 CN CN202280059679.4A patent/CN117881421A/zh active Pending
- 2022-09-01 EP EP22862431.8A patent/EP4395814A4/en active Pending
- 2022-09-01 MX MX2023015028A patent/MX2023015028A/es unknown
- 2022-09-01 AU AU2022341030A patent/AU2022341030A1/en active Pending
- 2022-09-01 CN CN202280053364.9A patent/CN117813109A/zh active Pending